MX2023002006A - Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. - Google Patents
Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.Info
- Publication number
- MX2023002006A MX2023002006A MX2023002006A MX2023002006A MX2023002006A MX 2023002006 A MX2023002006 A MX 2023002006A MX 2023002006 A MX2023002006 A MX 2023002006A MX 2023002006 A MX2023002006 A MX 2023002006A MX 2023002006 A MX2023002006 A MX 2023002006A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- methods
- compositions
- cns disorders
- treating cns
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/19—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/385—Saturated compounds containing a keto group being part of a ring
- C07C49/487—Saturated compounds containing a keto group being part of a ring containing hydroxy groups
- C07C49/507—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic
- C07C49/513—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/004—Expansion of ring B by one atom, e.g. B homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/006—Expansion of ring C by one atom, e.g. C homo steroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
- C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de la Fórmula (I-I): (ver Fórmula) (I-I) y sus sales farmacéuticamente aceptables, donde t, R7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a, R18b, R19a, R19b, R5a, R5b, R8 y R13 tienen los valores que se definen en la memoria descriptiva. Composiciones farmacéuticas que comprenden un compuesto de Fórmula (I-I) y métodos para usar los compuestos, por ejemplo en el tratamiento de trastornos relacionados con el sistema nervioso central.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762610067P | 2017-12-22 | 2017-12-22 | |
US201762612067P | 2017-12-29 | 2017-12-29 | |
US201762611977P | 2017-12-29 | 2017-12-29 | |
US201762612070P | 2017-12-29 | 2017-12-29 | |
US201762612164P | 2017-12-29 | 2017-12-29 | |
US201862765164P | 2018-08-17 | 2018-08-17 | |
US201862728499P | 2018-09-07 | 2018-09-07 | |
US201862737559P | 2018-09-27 | 2018-09-27 | |
US201862754977P | 2018-11-02 | 2018-11-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023002006A true MX2023002006A (es) | 2023-02-27 |
Family
ID=65234664
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006608A MX2020006608A (es) | 2017-12-22 | 2018-12-21 | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
MX2023002004A MX2023002004A (es) | 2017-12-22 | 2020-07-13 | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
MX2023002006A MX2023002006A (es) | 2017-12-22 | 2020-07-13 | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006608A MX2020006608A (es) | 2017-12-22 | 2018-12-21 | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
MX2023002004A MX2023002004A (es) | 2017-12-22 | 2020-07-13 | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220315621A1 (es) |
EP (1) | EP3728285A1 (es) |
JP (2) | JP2021506904A (es) |
KR (1) | KR20200104349A (es) |
CN (2) | CN111741965B (es) |
AR (1) | AR114044A1 (es) |
AU (2) | AU2018392093B2 (es) |
BR (1) | BR112020012761A2 (es) |
CA (1) | CA3086189A1 (es) |
IL (1) | IL275506A (es) |
MA (1) | MA51316A (es) |
MX (3) | MX2020006608A (es) |
TW (1) | TW201938172A (es) |
WO (1) | WO2019126761A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2806877T3 (pl) | 2012-01-23 | 2020-06-01 | Sage Therapeutics, Inc. | Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny |
WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
LT3224269T (lt) | 2014-11-27 | 2020-07-10 | Sage Therapeutics, Inc. | Kompozicijos ir būdai, skirti cns sutrikimams gydyti |
IL302480A (en) | 2016-08-23 | 2023-06-01 | Sage Therapeutics Inc | 19-NOR C3, 3-Dimuter C21-N-Pyrazolyl Steroid Crystalline |
WO2019113494A1 (en) | 2017-12-08 | 2019-06-13 | Sage Therapeutics, Inc. | Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders |
WO2019140272A1 (en) | 2018-01-12 | 2019-07-18 | Sage Therapeutics, Inc. | Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders |
KR20200119272A (ko) * | 2018-02-11 | 2020-10-19 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 스테로이드 유도체 조절제, 그 제조 방법 및 그의 용도 |
EP3864022B1 (en) | 2018-10-12 | 2023-09-20 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
MA54594A (fr) | 2018-12-05 | 2022-04-06 | Sage Therapeutics Inc | Stéroïdes neuroactifs et leurs procédés d'utilisation |
JP2022516986A (ja) * | 2019-01-08 | 2022-03-03 | 成都康弘薬業集団股▲フン▼有限公司 | ステロイド化合物、その使用、およびその調製方法 |
MX2021014515A (es) | 2019-05-31 | 2022-03-22 | Sage Therapeutics Inc | Esteroides neuroactivos y composiciones de estos. |
EP3990468A1 (en) | 2019-06-27 | 2022-05-04 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
TW202114700A (zh) * | 2019-06-27 | 2021-04-16 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
TW202114696A (zh) * | 2019-06-27 | 2021-04-16 | 美商賽吉醫療公司 | 用於治療cns病症之組合物及方法 |
US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
WO2022246634A1 (en) * | 2021-05-25 | 2022-12-01 | Zhejiang Jiachi Development Pharmaceuticals Ltd. | Compositions for treating insomnia and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1380246A (en) * | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
DK134348C (da) * | 1973-11-30 | 1977-03-21 | Schering Ag | Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner |
IL48628A0 (en) * | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
GB1570394A (en) * | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
GB1581234A (en) * | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
GB1581235A (en) * | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
SG11201508550XA (en) * | 2013-04-17 | 2015-11-27 | Sage Therapeutics Inc | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
-
2018
- 2018-12-21 CA CA3086189A patent/CA3086189A1/en active Pending
- 2018-12-21 BR BR112020012761-2A patent/BR112020012761A2/pt unknown
- 2018-12-21 AR ARP180103829A patent/AR114044A1/es unknown
- 2018-12-21 WO PCT/US2018/067306 patent/WO2019126761A1/en active Application Filing
- 2018-12-21 CN CN201880089891.9A patent/CN111741965B/zh active Active
- 2018-12-21 MX MX2020006608A patent/MX2020006608A/es unknown
- 2018-12-21 US US16/955,736 patent/US20220315621A1/en not_active Abandoned
- 2018-12-21 JP JP2020534302A patent/JP2021506904A/ja not_active Withdrawn
- 2018-12-21 EP EP18839992.7A patent/EP3728285A1/en active Pending
- 2018-12-21 MA MA051316A patent/MA51316A/fr unknown
- 2018-12-21 CN CN202410098394.2A patent/CN118085004A/zh active Pending
- 2018-12-21 AU AU2018392093A patent/AU2018392093B2/en active Active
- 2018-12-21 KR KR1020207021155A patent/KR20200104349A/ko not_active Application Discontinuation
- 2018-12-22 TW TW107146684A patent/TW201938172A/zh unknown
-
2020
- 2020-06-18 IL IL275506A patent/IL275506A/en unknown
- 2020-07-13 MX MX2023002004A patent/MX2023002004A/es unknown
- 2020-07-13 MX MX2023002006A patent/MX2023002006A/es unknown
-
2023
- 2023-07-10 JP JP2023113057A patent/JP2023119042A/ja active Pending
- 2023-12-22 AU AU2023285947A patent/AU2023285947A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN118085004A (zh) | 2024-05-28 |
MX2023002004A (es) | 2023-02-27 |
TW201938172A (zh) | 2019-10-01 |
CN111741965B (zh) | 2024-06-25 |
MA51316A (fr) | 2020-10-28 |
RU2020123930A (ru) | 2022-01-26 |
CN111741965A (zh) | 2020-10-02 |
KR20200104349A (ko) | 2020-09-03 |
EP3728285A1 (en) | 2020-10-28 |
AU2023285947A1 (en) | 2024-01-25 |
AR114044A1 (es) | 2020-07-15 |
US20220315621A1 (en) | 2022-10-06 |
AU2018392093A1 (en) | 2020-07-09 |
RU2020123930A3 (es) | 2022-02-04 |
MX2020006608A (es) | 2020-11-06 |
BR112020012761A2 (pt) | 2021-02-17 |
AU2018392093B2 (en) | 2024-02-01 |
JP2021506904A (ja) | 2021-02-22 |
IL275506A (en) | 2020-08-31 |
CA3086189A1 (en) | 2019-06-27 |
WO2019126761A1 (en) | 2019-06-27 |
JP2023119042A (ja) | 2023-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023002006A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
MX2023005098A (es) | Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central. | |
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2020013014A (es) | N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2. | |
MX2021004492A (es) | Composiciones para el tratamiento de trastornos del snc. | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
MX2021006902A (es) | Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica. | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
MX2022005160A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2021015854A (es) | Composiciones y métodos para tratar trastornos del snc. | |
MX2021005052A (es) | Oxiesteroles y métodos de uso de los mismos. | |
NZ769042A (en) | Compositions and methods for treating cns disorders | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
JOP20180092A1 (ar) | مثبطات hiv بروتياز | |
MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
PH12017501422A1 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
PH12019500568A1 (en) | Dopamine-b-hydroxylase inhibitors | |
ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
MX2021015942A (es) | Composiciones y métodos para tratar trastornos del snc. | |
MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
MX2018014081A (es) | Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal. |